In 1978, Greyhound sold Armour Pharmaceuticals to Revlon. Revlon sold its drug unit in 1985 to Rorer (later known as Rhône-Poulenc Rorer). Forest Laboratories acquired the rights to Armour Thyroid from Rhone-Poulenc Rorer in 1991. The remaining assets of Armour Pharmaceuticals are now part of CSL Behring. Armour's Factor VIII product "Factorate" was widely reported as infecting thousands of hemophiliacs worldwide with HIV during the 1980s; there have also been allegations that the firm suppressed evidence showing the product was defective. As a result, there have been lawsuits, inquiries and criminal charges.